Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 238
- Registration Number
- NCT06733038
- Locations
- 🇮🇹
Istituto Oncologico Veneto Irccs, Padova, PD, Italy
🇮🇹Nuovo Ospedale di Prato S. Stefano, Prato, PO, Italy
🇮🇹U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy
A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients with Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 57
- Registration Number
- NCT06732856
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
First-line Treatment with RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 110
- Registration Number
- NCT06730373
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳Shengli Oilfield Central Hospital, Dongying, Shandong, China
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT06696768
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Target Recruit Count
- 70
- Registration Number
- NCT06684158
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT06662786
- Locations
- 🇲🇾
Hospital Pulau Pinang, Georgetown, Malaysia
🇲🇾Hospital Umum Sarawak, Kuching, Malaysia
🇲🇾Hospital Raja Permaisuri Bainun, Ipoh, Malaysia
CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC
- Conditions
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 124
- Registration Number
- NCT06652412
Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients with GI Malignancies
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- University of Vermont Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06648785
- Locations
- 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
🇺🇸University of Vermont, Burlington, Vermont, United States
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 180
- Registration Number
- NCT06628310
- Locations
- 🇺🇸
City of Hope National Medical Center /ID# 268690, Duarte, California, United States
🇺🇸Hattiesburg Clinic /ID# 268572, Hattiesburg, Mississippi, United States
🇺🇸Millennium Research & Clinical Development /ID# 268540, Houston, Texas, United States
Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT06625320
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.